↓ Skip to main content

Emerging treatment options for BRAF-mutant colorectal cancer

Overview of attention for article published in Gastrointestinal Cancer: Targets and Therapy, March 2018
Altmetric Badge

Mentioned by

news
8 news outlets
twitter
1 tweeter
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Emerging treatment options for <em>BRAF</em>-mutant colorectal cancer
Published in
Gastrointestinal Cancer: Targets and Therapy, March 2018
DOI 10.2147/gictt.s125940
Pubmed ID
Authors

Carling Ursem, Chloe E Atreya, Katherine Van Loon

Abstract

The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments. Colorectal cancer (CRC) is a disease that has historically been notable for its dearth of biomarkers that are predictive of response to targeted therapies. In recent years, BRAFV600E-mutated CRC has emerged as a distinct biologic entity, typically refractory to standard chemotherapy regimens approved for the treatment of metastatic CRC and associated with a dismal prognosis. Multiple clinical trials sought to replicate the successes of targeted therapies seen in BRAFV600E-mutated melanoma without success; metastatic BRAFV600E-mutated CRC is clearly a distinct biologic entity. We review a number of recent studies demonstrating the evidence of modest responses to combinations of BRAF, EGFR, and/or MEK inhibition in patients with metastatic BRAFV600E-mutated CRC; however, despite advances, overall survival remains far inferior for these patients compared to their BRAF-wild-type counterparts. Development of combination therapies to impede signaling through the MAPK pathway through alternate targets remains an area of active investigation. Reflecting the rapid evolution of efforts for this small subset of CRC patients, the first-ever Phase III study is now underway evaluating the combination of BRAF, EGFR, and MEK inhibition. Immunotherapies are also an area of active research, particularly for the subset of patients with tumors that are also microsatellite instability (MSI) high. Here, we summarize the current landscape and emerging data on the molecular, clinical, and therapeutic aspects of BRAF-mutant CRC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 9 18%
Student > Bachelor 8 16%
Student > Master 8 16%
Student > Ph. D. Student 7 14%
Student > Doctoral Student 5 10%
Other 14 27%
Readers by discipline Count As %
Medicine and Dentistry 18 35%
Biochemistry, Genetics and Molecular Biology 15 29%
Unspecified 12 24%
Agricultural and Biological Sciences 2 4%
Immunology and Microbiology 2 4%
Other 2 4%